1. Synergistic Activity of N-hydroxy-7-(2-naphthylthio) Heptanomide and Sorafenib Against Cancer Stem Cells, Anaplastic Thyroid Cancer
   Ki Cheong Park et al, 2017, Neoplasia CrossRef
2. Hypocalcemia During Lenvatinib Treatment for Advanced Thyroid Cancer: Clinical Features and Management in a Real-Life Setting
   Simone De Leo et al, 2023, Thyroid CrossRef
3. New approaches for patients with advanced radioiodine-refractory thyroid cancer
   Fabián Pitoia et al, 2022, World Journal of Clinical Oncology CrossRef
4. Sorafenib and radioiodine-refractory differentiated thyroid cancer (RR-DTC): a systematic review and meta-analysis
   Guoli Feng et al, 2020, Endocrine CrossRef
5. Lenvatinib-induced hypocalcaemia due to transient primary hypoparathyroidism
   Matteo Trevisan et al, 2022, Endocrine CrossRef
6. Predictors of Response and Survival to Multikinase Inhibitors in Radioiodine Resistant Differentiated Thyroid Cancer
   Tiziana Feola et al, 2021, Journal of Personalized Medicine CrossRef
7. Synergistic Anticancer Activity of N-Hydroxy-7-(2-Naphthylthio) Heptanomide, Sorafenib, and Radiation Therapy in Patient-Derived Anaplastic Thyroid Cancer Models
   Hyeok Jun Yun et al, 2021, International Journal of Molecular Sciences CrossRef
8. Modulation of Autophagy by Sorafenib: Effects on Treatment Response
   Nestor Prieto-Domínguez et al, 2016, Frontiers in Pharmacology CrossRef
9. Radioiodine Refractory Thyroid Cancer
   Fabian Pitoia et al, 2023, Practical Management of Thyroid Cancer CrossRef
10. Molecular characterization of autophagic and apoptotic signaling induced by sorafenib in liver cancer cells
    María A. Rodríguez‐Hernández et al, 2019, Journal of Cellular Physiology CrossRef